cyclopycnanthogenin

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: cyclopycnanthogenin
• 英文别名: cyclopycanthogenin；(1S,3R,8R,9S,11S,12S,14S,15R,16R)-9,14-dihydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethylpentacyclo[9.7.0.01,3.03,8.012,16]octadecan-6-one
• 化学式: C₃₀H₄₈O₅
• 分子量: 488.708
• InChiKey: ZMRLIGKFEWIBJX-ZTMCZERUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  cyclopycnanthogenin 在 二异丁基氢化铝 、 4-吡咯烷基吡啶 、 氟化氢吡啶 、 三乙胺 、 [双(2-甲氧基乙基)胺]三氟化硫 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 22.0h， 生成 (2aR,3R,4S,5aS,5bS,7S,7aR,11aR,12aS)-9,9-difluoro-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyltetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthrene-4,7-diol
  参考文献：
  名称：

  SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION

  摘要：

  本发明提供了一系列卤代四环三萜衍生物及其制备和应用。其通式如下：R1为卤素，R2为氢，卤素选自氟、氯、溴或碘；或R1和R2均为氟，R3为胺、醇、氨基酸、肽或磷酸，通过酰基连接到氧。通过药代动力学研究，这些衍生物在大鼠全血中相对稳定。单次口服给雄性和雌性大鼠后的绝对生物利用度分别为15.6％和28.4％。平均生物利用度为22％。与现有标准药物依那普利和沙库巴曲钠相比，这些衍生物在体内活性更好。同时，本发明还制备了四环三萜衍生物的亲水性前药。本发明的衍生物可用于制备心血管药物。

  公开号：

  US20220177511A1
• 作为产物：
  描述：

  环黄芪醇 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 生成 cyclopycnanthogenin
  参考文献：
  名称：

  Compositions and Methods for Increasing Telomerase Activity

  摘要：

  本发明涉及增加细胞中端粒酶活性的方法和组合物。这些组合物包括药物配方。这些方法和组合物对于治疗需要通过增加患者细胞或组织中端粒酶活性来治疗的疾病是有用的。它们还可用于增强培养中细胞的复制能力，如体外细胞治疗，以及增强干细胞和祖细胞的增殖。

  公开号：

  US20100292197A1

文献信息

• Compositions and Methods for Increasing Telomerase Activity
  申请人：Harley Calvin B.

  公开号：US20100292197A1

  公开（公告）日：2010-11-18

  The present invention relates to methods and compositions for increasing telomerase activity in cells. Such compositions include pharmaceutical formulations. The methods and compositions are useful for treating diseases subject to treatment by an increase in telomerase activity in cells or tissue of a patient. They are also useful for enhancing replicative capacity of cells in culture, as in ex vivo cell therapy and for enhancing proliferation of stem and progenitor cells.

  本发明涉及增加细胞中端粒酶活性的方法和组合物。这些组合物包括药物配方。这些方法和组合物对于治疗需要通过增加患者细胞或组织中端粒酶活性来治疗的疾病是有用的。它们还可用于增强培养中细胞的复制能力，如体外细胞治疗，以及增强干细胞和祖细胞的增殖。
• Functional Characterization and Protein Engineering of a Triterpene 3‐/6‐/2′‐ <i>O</i> ‐Glycosyltransferase Reveal a Conserved Residue Critical for the Regiospecificity
  作者：Meng Zhang、Yang Yi、Bai‐Han Gao、Hui‐Fei Su、Yang‐Oujie Bao、Xiao‐Meng Shi、Hai‐Dong Wang、Fu‐Dong Li、Min Ye、Xue Qiao

  DOI：10.1002/anie.202113587

  日期：2022.2.14

  We characterized the first plant cycloartane glycosyltransferase AmGT8 from A. membranaceus. Its mutants A394F, A394D, and T131V were discovered using semi-rational design, which showed specific 6-O, 3-O, and 2′-O glycosylation activities, respectively. This study uncovered a conserved residue critical for the regiospecificity of plant glycosyltransferases.

  我们对来自A. membranaceus的第一个植物环阿坦糖基转移酶 AmGT8 进行了表征。其突变体 A394F、A394D 和 T131V 是使用半理性设计发现的，它们分别显示出特定的 6- O、3 - O和 2' - O糖基化活性。这项研究发现了一个对植物糖基转移酶的区域特异性至关重要的保守残基。
• ——
  作者：R. P. Mamedova、M. A. Agzamova、M. I. Isaev

  DOI：10.1023/a:1014864731925

  日期：——

  The partial synthesis of cyclopycanthogenin, 20R,24S-epoxycycloartan-6alpha, 16beta,25-triol-3-one, was developed in four steps from cyclosiversigenin.
• Microbial transformation of cycloastragenol
  作者：Melis Kuban、Gaye Öngen、Ikhlas A. Khan、Erdal Bedir

  DOI：10.1016/j.phytochem.2012.12.007

  日期：2013.4

  The microbial transformation of cycloastragenol by the fungi Cunninghamella blakesleeana NRRL 1369 and Glomerella fusarioides ATCC 9552, and the bacterium Mycobacterium sp. NRRL 3805 were investigated. Both fungi mainly provided hydroxylated metabolites together with products formed by cyclization, dehydrogenation and Baeyer-Villiger oxidation resulting in a ring cleavage. The bacteria yielded only a single oxidation product, namely, 3-oxo-cycloastragenol. Structures of the metabolites were elucidated by 1-D (H-1,C-13), 2-D NMR (COSY, HMBC, HMQC) and HRMS analyses. (C) 2013 Elsevier Ltd. All rights regerved.
• SERIES OF HALOGENATED TETRACYCLIC TRITERPENE DERIVATIVES AND THEIR PREPARATION AND APPLICATION
  申请人：SHANGHAI KING-X BIOTECH CO., LTD

  公开号：US20220177511A1

  公开（公告）日：2022-06-09

  The invention provides a series of halogenated tetracyclic triterpene derivatives and their preparation and application. It is represented by the following general structural formula: R 1 is halogen, R 2 is H, and the halogen is selected from fluorine, chlorine, bromine or iodine; or R 1 and R 2 are each fluorine, and R 3 is an amine, alcohol, amino acid, peptide or phosphate linked to oxygen through an acyl group. The derivatives are relatively stable in rat whole blood through pharmacokinetic studies. The absolute bioavailability after a single intragastric administration for male and female rats was 15.6% and 28.4% respectively. The mean bioavailability was 22%. The derivatives showed better in vivo activities compared with the existing standard drugs enalapril and sacubitril valsartan sodium. Meanwhile, hydrophilic prodrugs of the tetracyclic triterpenoid derivatives in the present invention were prepared. The derivatives of the present invention can be used for preparing cardiovascular medicines.

  本发明提供了一系列卤代四环三萜衍生物及其制备和应用。其通式如下：R1为卤素，R2为氢，卤素选自氟、氯、溴或碘；或R1和R2均为氟，R3为胺、醇、氨基酸、肽或磷酸，通过酰基连接到氧。通过药代动力学研究，这些衍生物在大鼠全血中相对稳定。单次口服给雄性和雌性大鼠后的绝对生物利用度分别为15.6％和28.4％。平均生物利用度为22％。与现有标准药物依那普利和沙库巴曲钠相比，这些衍生物在体内活性更好。同时，本发明还制备了四环三萜衍生物的亲水性前药。本发明的衍生物可用于制备心血管药物。